If you're one of the 33 million Americans enrolled in a Medicare Advantage plan in 2026, a quiet regulatory decision made in Washington has real consequences for your healthcare. The Centers for Medicare & Medicaid Services has suspended new prior authorization transparency rules that were designed to force Medicare Advantage insurers to publicly disclose how frequently they deny coverage requests — and under what circumstances. The suspension came amid what regulators described as public concerns, though critics argue the insurance industry's lobbying pressure played a significant role in the pause. Whatever the reason, the practical effect is the same: you now have less publicly available information to judge whether your Medicare Advantage plan is approving or blocking the care your doctors recommend.
To understand why this matters, it helps to know what prior authorization actually is and how it works inside Medicare Advantage. When you enroll in a Medicare Advantage plan — whether that's an HMO, PPO, PFFS, or SNP — you're agreeing to receive your Medicare benefits through a private insurer rather than directly through the federal government. These insurers are permitted by law to require prior authorization, meaning your doctor must get the plan's approval before you receive certain services, procedures, medications, or referrals to specialists. Original Medicare, by contrast, does not require prior authorization for most services. The trade-off for accepting prior authorization requirements is typically lower premiums and added benefits like dental, vision, or gym memberships that Original Medicare doesn't cover.
The problem is that prior authorization denials have become a significant and well-documented source of harm for Medicare Advantage enrollees. A 2022 report from the HHS Office of Inspector General found that Medicare Advantage plans denied 13% of prior authorization requests that met Medicare coverage rules — meaning care that should have been approved under federal standards was being blocked. The same report found that when beneficiaries appealed those denials, plans overturned 75% of them. That's a staggering reversal rate, and it tells you something important: a large share of initial denials are not clinically justified. They're administrative obstacles that many beneficiaries simply don't know how to challenge, or give up on before the process is complete.
The transparency rules that CMS has now suspended were specifically designed to address this information gap. Under the paused regulations, Medicare Advantage plans would have been required to publicly report granular data on prior authorization requests — including how many were submitted, how many were denied, how many were appealed, and how many of those appeals succeeded. This data would have been broken down by service type, allowing beneficiaries, researchers, physicians, and policymakers to identify which plans were systematically blocking care and in what clinical categories. Orthopedic procedures, post-acute rehabilitation, home health services, and certain cancer treatments have historically been among the most frequently denied service categories in Medicare Advantage. With the transparency rules suspended, that comparative data will not be available in the standardized, publicly accessible format that was planned.
What does this mean for you right now, practically speaking? First, it means you need to be your own advocate more aggressively than before. If your Medicare Advantage plan denies a prior authorization request, you have the right to appeal — and the statistics suggest you have a strong chance of winning if you do. The appeals process has specific timelines you must follow. For a standard appeal (called a redetermination), you typically have 60 days from the date of the denial notice to file with your plan. For urgent or time-sensitive care, you can request an expedited appeal, and the plan must respond within 72 hours. If your plan upholds the denial, you can escalate to an independent review organization, then to an Administrative Law Judge, and ultimately to federal court. Most beneficiaries who win their appeals do so at the plan level or the independent review stage — so don't assume the first denial is the final word.
Second, the suspension of these transparency rules makes the plan comparison process harder during the Annual Enrollment Period, which runs October 15 through December 7 each year. In prior years, advocacy groups and researchers had begun compiling denial rate data from CMS disclosures to help beneficiaries identify plans with problematic authorization practices. With the new, more detailed reporting requirements on hold, that kind of comparative analysis becomes more difficult. However, some data remains available. CMS still publishes Medicare Advantage plan star ratings, which include measures related to appeals and access to care. A plan's star rating — on a scale of 1 to 5 — incorporates member complaints, appeals outcomes, and care coordination metrics. When comparing plans during AEP, look specifically at the "Access to Care" and "Member Complaints" domains within the star rating system, not just the overall star score. A plan with a 4-star overall rating could still have a 2-star score in member complaints, which is a red flag worth investigating.
Third, if you're currently enrolled in a Medicare Advantage plan and experiencing repeated prior authorization problems, you have options beyond just appealing individual denials. The Medicare Open Enrollment Period, which runs January 1 through March 31 each year, allows you to switch from Medicare Advantage back to Original Medicare or move to a different Medicare Advantage plan. This is sometimes called the Medicare Advantage Open Enrollment Period, and it's distinct from the Annual Enrollment Period in the fall. If you switch back to Original Medicare during this window, you'll want to think carefully about Medigap (Medicare Supplement) coverage, because Original Medicare alone leaves you exposed to significant cost-sharing — including a $1,676 Part A deductible per benefit period and 20% coinsurance for most Part B services in 2026 with no out-of-pocket maximum.
Medigap eligibility is where things get complicated, and the suspension of prior authorization transparency rules makes this conversation more urgent for some beneficiaries. In most states, if you're past your initial Medigap open enrollment window (which is the six months after you first enroll in Part B), insurers can use medical underwriting to deny you a Medigap policy or charge you higher premiums based on your health history. This means that if you've developed chronic conditions while enrolled in Medicare Advantage, switching back to Original Medicare with a Medigap supplement may not be straightforward. However, 13 states have enacted protections that create additional guaranteed-issue windows. The so-called birthday rule states — California, Idaho, Illinois, Kentucky, Louisiana, Maine, Maryland, Missouri, Nevada, New Jersey, New York, Oklahoma, and Oregon — give beneficiaries a 30-day window around their birthday each year to switch Medigap plans without medical underwriting. New York and Connecticut go further, requiring guaranteed issue for Medigap year-round. If you live in one of these states and are considering leaving Medicare Advantage due to prior authorization frustrations, your birthday window may be your best opportunity to secure Medigap coverage without being denied for pre-existing conditions.
For beneficiaries who want to stay in Medicare Advantage but need better tools to evaluate their plan's authorization practices, there are still some resources available despite the regulatory pause. Medicare's Plan Finder tool at medicare.gov allows you to compare plans side by side on cost, coverage, and star ratings. The State Health Insurance Assistance Program, known as SHIP, provides free one-on-one counseling in every state — counselors can help you review your current plan's prior authorization requirements, which are listed in the plan's Evidence of Coverage document, and compare them to alternatives in your area. Your plan's Evidence of Coverage is a legally required document that must list every service subject to prior authorization, and reviewing it annually is one of the most underutilized tools available to Medicare Advantage enrollees.
It's also worth understanding what CMS has said about why these transparency rules were suspended. The agency indicated it was responding to concerns raised during the public comment process, though it has not specified a revised timeline for when or whether the rules will be reinstated. Medicare policy advocates, including organizations that track Medicare Advantage oversight, have expressed concern that the suspension effectively removes a key accountability mechanism at a time when Medicare Advantage enrollment is at an all-time high and prior authorization complaints are rising. The Medicare Payment Advisory Commission, known as MedPAC, has repeatedly flagged prior authorization as a systemic problem in Medicare Advantage and has recommended that Congress and CMS take stronger action to limit inappropriate denials.
For now, the most important thing you can do is treat every prior authorization denial as a starting point, not an ending point. Request the denial in writing, ask your doctor to submit a letter of medical necessity with your appeal, and keep copies of everything. If your plan denies an appeal and you believe the care is medically necessary, escalate to the Qualified Independent Contractor review stage — this is the independent review organization level — where a clinician outside your insurance company will evaluate your case. The 1-800-MEDICARE helpline (1-800-633-4227) can walk you through the appeals process step by step and connect you with your state's SHIP program for personalized guidance. In a regulatory environment where transparency requirements have been paused, your own persistence and knowledge of the appeals process is the most reliable protection you have.